BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26113530)

  • 1. Toward optimizing pomalidomide therapy in MM patients.
    Podar K
    Blood; 2015 Jun; 125(26):3968-9. PubMed ID: 26113530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
    Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M; Couto S; Breider M; Hansel D; Seropian S; Cooper D; Thakurta A; Yao X; Dhodapkar KM; Dhodapkar MV
    Blood; 2015 Jun; 125(26):4042-51. PubMed ID: 25869284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
    Mark TM; Coleman M; Niesvizky R
    Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide: when expectations are understated.
    Di Raimondo F; Conticello C
    Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
    [No Abstract]   [Full Text] [Related]  

  • 6. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
    Sun JJ; Zhang C; Zhou J; Yang HL
    Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
    Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
    Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
    Baertsch MA; Hundemer M; Hillengass J; Goldschmidt H; Raab MS
    Hematol Oncol; 2018 Feb; 36(1):258-261. PubMed ID: 28840598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide-based therapy for extramedullary multiple myeloma.
    Li Y; Ji J; Lu H; Li J; Qu X
    Hematology; 2022 Dec; 27(1):88-94. PubMed ID: 35068387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
    Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
    Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
    [No Abstract]   [Full Text] [Related]  

  • 11. Pomalidomide in the management of relapsed multiple myeloma.
    Touzeau C; Moreau P
    Future Oncol; 2016 Sep; 12(17):1975-83. PubMed ID: 27283457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of pomalidomide in a multiple myeloma patient requiring hemodialysis].
    Kida M; Hirao M; Iizuka H; Hangaishi A; Usuki K
    Rinsho Ketsueki; 2016; 57(11):2339-2344. PubMed ID: 27941283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent studies on the thalidomide and its derivatives.
    Łączkowski KZ; Baranowska-Łączkowska A
    Future Med Chem; 2018 Sep; 10(18):2133-2136. PubMed ID: 30088422
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
    Kumar A; Porwal M; Verma A; Mishra AK
    J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pomalidomide].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():330-4. PubMed ID: 30615392
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.